Shaik Asha Begum, T. Vinay Kumar, Shaik Abdul Rahaman, S. Joshna Rani, Sreya Kosanam, Y. Veena
Shaik Asha Begum1,3*, T. Vinay Kumar1, Shaik Abdul Rahaman4, S. Joshna Rani3, Sreya Kosanam1, Y. Veena1
1Department of Pharmacology and Pharmacy Practice, Nirmala College of Pharmacy, Atmakur, Mangalagiri, AP, India – 522503.
2 Pharm D Students, Nirmala College of Pharmacy, Atmakur, Mangalagiri, AP, India - 522503
3IPT, SPMVV, Tirupati, AP, India – 517501.
4Princiapl and Professor, Nirmala College of Pharmacy, Atmakur, Mangalagiri, AP, India – 522503.
Volume - 14,
Issue - 4,
Year - 2022
Guillain-Baree syndrome also called guillain–Barré–Strohl syndrome, Landry's paralysis, post - infectious polyneuritis whichis a rare, at one or two cases per 100, 000 people every year, where auto-immune disorder in which a persons own immune system damaged the nerves, causing muscule weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage. some people have died of GBS. Several things are known to tigger GBS. About two-thirds of people with GBS had diarrhea or a respiratory illness several weeks before developing symptoms. Infection with campylobacter jejuni, which causes diarrhea, is one of the most common risk factors for GBS. People can develop GBS after some other infections, such as flu, cytomegalovirus, Epstein barr virus, and zika virus. Very rarely, people have developed GBS in the days or weeks after receiving certain vaccines. It can be caused by campylobacter infection that is diagnosed when a laboratory tests detect campylobacter bacteria in stool, body tissue, or fluids. The test could be a culture that isolates the bacteria or a rapid diagnostic test that detects genetic material of the bacteria. The major aim of this case report is to present a classic case of this condition, to highlight an awareness of differing treatment options, and to advocate referral to a given its physician potential severity. Treatment for GBS including antibiotics, drink extra fluids as long as diarrhea lasts, plasma exchange, immunoglobulin therapy2.
Cite this article:
Shaik Asha Begum, T. Vinay Kumar, Shaik Abdul Rahaman, S. Joshna Rani, Sreya Kosanam, Y. Veena. Gullian Barr Syndrome – A Rare Disease Case Report. Research Journal of Pharmacology and Pharmacodynamics.2022;14(4):234-6. doi: 10.52711/2321-5836.2022.00040
Shaik Asha Begum, T. Vinay Kumar, Shaik Abdul Rahaman, S. Joshna Rani, Sreya Kosanam, Y. Veena. Gullian Barr Syndrome – A Rare Disease Case Report. Research Journal of Pharmacology and Pharmacodynamics.2022;14(4):234-6. doi: 10.52711/2321-5836.2022.00040 Available on: https://rjppd.org/AbstractView.aspx?PID=2022-14-4-6
1. Avinash. B. Thalkari, Pawan. N. Karwa, Chandrakant S. Gawli. Anonychia Congenita: A Rare Disease. Res. J. Pharmacology and Pharmacodynamics. 2020; 12(2): 55-56. doi: 10. 5958/2321-5836. 2020. 00011. 7
2. Tejasavi Mahajan, Navdeep Singh, Kamya Goyal, Shammy Jindal, Vinay Pandit, M. S. Ashawat. Recent Updates on Psoriasis: A Review. Asian Journal of Pharmaceutical Research. 2022; 12(1):76-3. doi: 10. 52711/2231-5691. 2022. 00012
3. Girish Yogesh Pawar, Rushikesh Rakesh Chaudhari, Tushar Naresh Sonawane, Jayesh Shyam Desale, Suraj K. Ishikar. A Short Review on Study on Different Clinical Trials Performed on Drugs before it Comes into The Market. Asian Journal of Pharmaceutical Research. 2022; 12(1):84-7. doi: 10. 52711/2231-5691. 2022. 00013
4. Ganesh G. Dhakad, Sangita P. Shirsat, Kaveri P. Tambe, Vinit Kairnar, Ritik. S. Jain. Review on Immuno-Oncology agents for Cancer Therapy. Asian Journal of Pharmaceutical Research. 2022; 12(1):110-5. doi: 10. 52711/2231-5691. 2022. 00017
5. Santhosh Kumar V, Praveen D. Sugar and Chronic Diseases. Research J. Pharm. and Tech. 2016; 9(6): 650-654. doi: 10. 5958/0974-360X. 2016. 00123. 2
6. Sukhbir Lal Khokra, Bharat Parashar, Hitesh Kumar Dhamija, Manju Bala. Immunomodulators: Immune System Modifiers. Research J. Pharm. and Tech. 5(2): Feb. 2012; Page 169-174. doi: Not Available
7. Lippi G, Plebani M. Biomarker research and leading causes of death worldwide: a rather feeble relationship. Clin Chem Lab Med 2013;51:1691-3. 10. 1515/cclm-2013-0210 [PubMed] [CrossRef] [Google Scholar]
8. Tong N. Priority Diseases and Reasons for Inclusion. In: Priority Medicines for Europe and the World 2013 Update. World Health Organization Publisher, Geneva, Switzerland, 2013. [Google Scholar]